BNP Paribas Arbitrage SA lessened its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 19.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,921 shares of the medical research company’s stock after selling 1,873 shares during the period. BNP Paribas Arbitrage SA’s holdings in Bio-Rad Laboratories were worth $5,985,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also bought and sold shares of the company. Spire Wealth Management raised its stake in Bio-Rad Laboratories by 312.5% in the 4th quarter. Spire Wealth Management now owns 33 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 25 shares during the period. Altshuler Shaham Ltd bought a new stake in Bio-Rad Laboratories in the 3rd quarter valued at $46,000. CI Investments Inc. bought a new stake in Bio-Rad Laboratories in the 3rd quarter valued at $70,000. JJJ Advisors Inc. raised its stake in Bio-Rad Laboratories by 39.8% in the 4th quarter. JJJ Advisors Inc. now owns 116 shares of the medical research company’s stock valued at $88,000 after acquiring an additional 33 shares during the period. Finally, UMB Bank N A MO bought a new stake in Bio-Rad Laboratories in the 4th quarter valued at $113,000. Institutional investors and hedge funds own 63.66% of the company’s stock.
BIO has been the topic of a number of research analyst reports. Zacks Investment Research upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating and set a $526.00 price target on the stock in a research note on Wednesday, May 4th. StockNews.com assumed coverage on Bio-Rad Laboratories in a report on Thursday, March 31st. They issued a “hold” rating on the stock. Citigroup decreased their price objective on Bio-Rad Laboratories from $800.00 to $750.00 in a report on Monday, May 2nd. TheStreet lowered Bio-Rad Laboratories from a “b-” rating to a “c+” rating in a report on Thursday, April 28th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $700.00 price objective on shares of Bio-Rad Laboratories in a report on Friday, April 29th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Bio-Rad Laboratories currently has an average rating of “Buy” and an average price target of $726.50.
Bio-Rad Laboratories (NYSE:BIO – Get Rating) last released its earnings results on Thursday, April 28th. The medical research company reported $4.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.80 by $2.14. The company had revenue of $700.10 million for the quarter, compared to analyst estimates of $678.00 million. Bio-Rad Laboratories had a positive return on equity of 3.66% and a negative net margin of 3.49%. Bio-Rad Laboratories’s quarterly revenue was down 3.7% on a year-over-year basis. During the same period in the prior year, the firm posted $5.21 EPS. On average, research analysts expect that Bio-Rad Laboratories, Inc. will post 14.2 earnings per share for the current year.
Bio-Rad Laboratories Profile (Get Rating)
Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.
- Get a free copy of the StockNews.com research report on Bio-Rad Laboratories (BIO)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.